CNSP icon

CNS Pharmaceuticals
CNSP

Overview Fund Trends Analyst Outlook Journalist POV

7 hedge funds and large institutions have $55.2K invested in CNS Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

more ownership

Funds ownership: →

less funds holding

Funds holding: →

less first-time investments, than exits

New positions opened: | Existing positions closed:

less capital invested

Capital invested by funds: $ → $
Holders
7
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$30.9K
2
+$15.4K
3
+$6.95K
4
BC
Barrett & Company
Rhode Island
+$136
5
SS
SBI Securities
Japan
+$20

Top Sellers

1
-$50.5K
2
-$46.6K
3
-$38.8K
4
XT
XTX Topco
Cayman Islands
-$35.5K
5
CCM
Connective Capital Management
California
-$33.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$32.6K
GSC
2
Ground Swell Capital
South Carolina
$15.4K
TRCT
3
Tower Research Capital (TRC)
New York
$6.95K
BC
4
Barrett & Company
Rhode Island
$136
MCM
5
MAI Capital Management
Ohio
$55
SS
6
SBI Securities
Japan
$20
Bank of America
7
Bank of America
North Carolina
$12
Jane Street
8
Jane Street
New York
–
Geode Capital Management
9
Geode Capital Management
Massachusetts
–
Citadel Advisors
10
Citadel Advisors
Florida
–
XT
11
XTX Topco
Cayman Islands
–
CCM
12
Connective Capital Management
California
–
IWC
13
Integrated Wealth Concepts
Massachusetts
–
VF
14
Virtu Financial
New York
–
HF
15
HRT Financial
New York
–
Two Sigma Investments
16
Two Sigma Investments
New York
–
Goldman Sachs
17
Goldman Sachs
New York
–
SIM
18
Synergy Investment Management
Florida
–